BRCA2 and breast carcinoma: Combining SOC with gefitinib in BRCA2-mut ER+/HER2+ breast cancer cell lines also caused mostly synergistic growth inhibition, accompanied by induction of DNA damage, G1 arrest and apoptosis (Supplementary Fig. 13h–j).